These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36755290)

  • 1. N-terminal pro-B-type natriuretic peptide levels in normotensive and hypertensive dogs with myxomatous mitral valve disease stage B.
    Jang IS; Yoon WK; Choi EW
    Ir Vet J; 2023 Feb; 76(1):3. PubMed ID: 36755290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of N-terminal pro-atrial natriuretic peptide and three cardiac biomarkers for discriminatory ability of clinical stage in dogs with myxomatous mitral valve disease.
    Ogawa M; Hori Y; Kanno N; Iwasa N; Toyofuku T; Isayama N; Yoshikawa A; Akabane R; Sakatani A; Miyakawa H; Hsu HH; Miyagawa Y; Takemura N
    J Vet Med Sci; 2021 Apr; 83(4):705-715. PubMed ID: 33551383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How accurate are NT-proBNP, ANP, and cTnI levels in diagnosing dogs with myxomatous mitral valve disease?
    Chanmongkolpanit K; Riengvirodkij N; Channgam P; Kaenchan P; Buayam W; Janhirun Y; Phonarknguen R; Tansakul M; Sakcamduang W
    Open Vet J; 2024 Jun; 14(6):1426-1441. PubMed ID: 39055758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The predictive value of clinical, radiographic, echocardiographic variables and cardiac biomarkers for assessing risk of the onset of heart failure or cardiac death in dogs with preclinical myxomatous mitral valve disease enrolled in the DELAY study.
    Borgarelli M; Ferasin L; Lamb K; Chiavegato D; Bussadori C; D'Agnolo G; Migliorini F; Poggi M; Santilli RA; Guillot E; Garelli-Paar C; Toschi Corneliani R; Farina F; Zani A; Dirven M; Smets P; Guglielmini C; Oliveira P; Di Marcello M; Porciello F; Crosara S; Ciaramella P; Piantedosi D; Smith S; Vannini S; Dall'Aglio E; Savarino P; Quintavalla C; Patteson M; Silva J; Locatelli C; Baron Toaldo M
    J Vet Cardiol; 2021 Aug; 36():77-88. PubMed ID: 34118562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic value of atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP) and their correlation with lipoproteins in dogs with myxomatous mitral valve disease.
    Khaki Z; Nooshirvani P; Shirani D; Masoudifard M
    BMC Vet Res; 2022 Dec; 18(1):448. PubMed ID: 36564735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of physical examination, electrocardiography, radiography, and biomarkers to predict echocardiographic stage B2 myxomatous mitral valve disease in preclinical Cavalier King Charles Spaniels.
    Wesselowski S; Gordon SG; Fries R; Saunders AB; Sykes KT; Vitt J; Boutet B; Häggström J; Kadotani S; Stack J; Barnett BG
    J Vet Cardiol; 2023 Dec; 50():1-16. PubMed ID: 37913604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma humanin as a prognostic biomarker for canine myxomatous mitral valve disease: a comparison with plasma NT-roBNP.
    Mangkhang K; Punyapornwithaya V; Tankaew P; Pongkan W; Chattipakorn N; Boonyapakorn C
    Pol J Vet Sci; 2018 Dec; 21(4):673-680. PubMed ID: 30605282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The diagnostic relevance of NT-proBNP and proANP 31-67 measurements in staging of myxomatous mitral valve disease in dogs.
    Wolf J; Gerlach N; Weber K; Klima A; Wess G
    Vet Clin Pathol; 2013 Jun; 42(2):196-206. PubMed ID: 23614733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can cartilage intermediate layer protein 1 (CILP1) use as a novel biomarker for canine myxomatous mitral valve degeneration levels or not?
    Kim HJ; Kim J; Kim S; Kim HJ
    BMC Vet Res; 2023 Mar; 19(1):59. PubMed ID: 36882760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DELay of Appearance of sYmptoms of Canine Degenerative Mitral Valve Disease Treated with Spironolactone and Benazepril: the DELAY Study.
    Borgarelli M; Ferasin L; Lamb K; Bussadori C; Chiavegato D; D'Agnolo G; Migliorini F; Poggi M; Santilli RA; Guillot E; Garelli-Paar C; Toschi Corneliani R; Farina F; Zani A; Dirven M; Smets P; Guglielmini C; Oliveira P; Di Marcello M; Porciello F; Crosara S; Ciaramella P; Piantedosi D; Smith S; Vannini S; Dall'Aglio E; Savarino P; Quintavalla C; Patteson M; Silva J; Locatelli C; Baron Toaldo M
    J Vet Cardiol; 2020 Feb; 27():34-53. PubMed ID: 32032923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of dogs with compensated myxomatous mitral valve disease with spironolactone-a pilot study.
    Hezzell MJ; Boswood A; López-Alvarez J; Lötter N; Elliott J
    J Vet Cardiol; 2017 Aug; 19(4):325-338. PubMed ID: 28734620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of prespecified therapy escalation on plasma NT-proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease.
    Hezzell MJ; Block CL; Laughlin DS; Oyama MA
    J Vet Intern Med; 2018 Sep; 32(5):1509-1516. PubMed ID: 30216549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-Term Effects of Sacubitril
    Saengklub N; Pirintr P; Nampimoon T; Kijtawornrat A; Chaiyabutr N
    Front Vet Sci; 2021; 8():700230. PubMed ID: 34386539
    [No Abstract]   [Full Text] [Related]  

  • 14. Lowered N-terminal pro-B-type natriuretic peptide levels in response to treatment predict survival in dogs with symptomatic mitral valve disease.
    Wolf J; Gerlach N; Weber K; Klima A; Wess G
    J Vet Cardiol; 2012 Sep; 14(3):399-408. PubMed ID: 22858663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-terminal pro-B-type natriuretic peptide and its relationship with cardiac function in adults with congenital heart disease.
    Eindhoven JA; van den Bosch AE; Ruys TP; Opić P; Cuypers JA; McGhie JS; Witsenburg M; Boersma E; Roos-Hesselink JW
    J Am Coll Cardiol; 2013 Sep; 62(13):1203-12. PubMed ID: 23916937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Paraoxonase-1 and NT-proBNP with Clinical, Clinico-Pathologic and Echocardiographic Variables in Dogs with Mitral Valve Disease.
    Rammal D; Koutinas CK; Athanasiou LV; Tangalidi M; Rubio CP; Cerón JJ; Tamvakis A; Patsikas MN; Polizopoulou ZS
    Vet Sci; 2023 Jan; 10(1):. PubMed ID: 36669034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between glomerular filtration rate and plasma N-terminal pro B-type natriuretic peptide concentrations in dogs with chronic kidney disease.
    Miyagawa Y; Tominaga Y; Toda N; Takemura N
    Vet J; 2013 Aug; 197(2):445-50. PubMed ID: 23570775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain-natriuretic peptide and cyclic guanosine monophosphate as biomarkers of myxomatous mitral valve disease in dogs.
    Moesgaard SG; Falk T; Teerlink T; Guðmundsdóttir HH; Sigurðardóttir S; Rasmussen CE; Olsen LH
    Vet J; 2011 Sep; 189(3):349-52. PubMed ID: 20822939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic Value of Selected Echocardiographic Variables to Identify Pulmonary Hypertension in Dogs with Myxomatous Mitral Valve Disease.
    Tidholm A; Höglund K; Häggström J; Ljungvall I
    J Vet Intern Med; 2015; 29(6):1510-7. PubMed ID: 26365438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of standard-dose and high-dose pimobendan on select indices of renal and cardiac function in dogs with American College of Veterinary Internal Medicine stage B2 myxomatous mitral valve disease.
    Kaplan JL; Visser LC; Gunther-Harrington CT; Ontiveros ES; Wittenburg LA; Palm CA; Stern JA
    J Vet Intern Med; 2022 Nov; 36(6):1892-1899. PubMed ID: 36098206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.